Earnings Troubles May Signal Larger Issues for LanZhou Foci PharmaceuticalLtd (SZSE:002644) Shareholders
Earnings Troubles May Signal Larger Issues for LanZhou Foci PharmaceuticalLtd (SZSE:002644) Shareholders
The subdued market reaction suggests that LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) recent earnings didn't contain any surprises. We think that investors are worried about some weaknesses underlying the earnings.
市場反應平淡,這表明佛慈制藥最近的收益沒有帶來任何驚喜。我們認爲投資者對收益背後的一些弱點感到擔憂。
The Impact Of Unusual Items On Profit
除了稀釋之外,還應該注意的是,萬集科技在過去12個月中因不尋常項目獲得了價值人民幣3.5萬元的利潤。雖然我們希望看到利潤增加,但當這些不尋常項目對利潤做出重大貢獻時,我們會更加謹慎。我們對全球大部分上市公司的數據進行了分析,發現不尋常項目往往是一次性的。這正如我們所期望的那樣,因爲這些提升被描述爲"不尋常"。相對於其利潤而言,萬集科技在2021年12月前的不尋常項目貢獻大。因此,我們可以推斷出,這些不尋常項目正在使其財務利潤顯著增強。
For anyone who wants to understand LanZhou Foci PharmaceuticalLtd's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥7.0m worth of unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And that's as you'd expect, given these boosts are described as 'unusual'. If LanZhou Foci PharmaceuticalLtd doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.
對於想要了解佛慈制藥除了法定數字之外的利潤的人來說,重要的是要注意,在過去的十二個月裏,法定利潤中從價值爲700萬人民幣的非凡項目獲得的利潤。儘管獲得更高的利潤總是令人愉快的,但非凡項目的大額貢獻有時會減少我們的熱情。當我們對成千上萬上市公司進行數據分析時,我們發現,一個年度中非凡項目的推動通常在下一年不會重複。這也是可以理解的,畢竟這些推動被描述爲「非凡」。如果佛慈制藥在未來的年份裏沒有看到這種貢獻重複,那麼其他條件相等的情況下,我們預計其利潤將在當前年份下降。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of LanZhou Foci PharmaceuticalLtd.
注意:我們始終建議投資者檢查資產負債表的實力。點擊這裏查看我們對佛慈制藥的資產負債表分析。
Our Take On LanZhou Foci PharmaceuticalLtd's Profit Performance
我們對佛慈制藥的利潤表現的看法
We'd posit that LanZhou Foci PharmaceuticalLtd's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Therefore, it seems possible to us that LanZhou Foci PharmaceuticalLtd's true underlying earnings power is actually less than its statutory profit. In further bad news, its earnings per share decreased in the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you want to do dive deeper into LanZhou Foci PharmaceuticalLtd, you'd also look into what risks it is currently facing. For example, LanZhou Foci PharmaceuticalLtd has 2 warning signs (and 1 which doesn't sit too well with us) we think you should know about.
我們認爲,由於存在大額飛凡項目,佛慈制藥的法定收益並不能清晰反映當前的生產力。因此,我們認爲,佛慈制藥的真實基本收益能力實際上低於其法定利潤。更糟糕的是,其每股收益在過去一年有所下降。當然,在分析其收益時,我們只是觸及了表面;人們還可以考慮利潤率、預測增長和投資回報等其他因素。如果你想深入研究佛慈制藥,你還需要了解它當前面臨的風險。例如,佛慈制藥有2個警示信號(以及1個我們認爲不太好的信號),我們認爲你應該知道。
This note has only looked at a single factor that sheds light on the nature of LanZhou Foci PharmaceuticalLtd's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
本文僅考慮了一個揭示佛慈制藥利潤本質的因素。但有許多其他方法可以了解一家公司。例如,許多人認爲高淨資產收益率是有利的商業經濟指標,而其他人則喜歡「追蹤資金」,尋找內部人員正在購買的股票。儘管這可能需要你進行一些研究,但你可能會發現這個免費的高淨資產收益率公司收藏或者擁有重要內部人持股的股票清單很有用。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。